Aceon (perindopril erbumine)
D/C if pregnancy is detected. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury/death to the developing fetus.
Treatment of essential HTN alone or w/ other antihypertensives (eg, thiazide diuretics). Treatment of stable coronary artery disease (CAD) to reduce risk of cardiovascular mortality or nonfatal MI; may be used w/ conventional treatment for CAD (eg, antiplatelet, antihypertensive, or lipid-lowering therapy).
Initial: 4mg qd
Titrate: May titrate prn to max of 16mg/day
Maint: 4-8mg/day given in 1 or 2 divided doses
Stable Coronary Artery Disease
Initial: 4mg qd for 2 weeks
Maint: Increase as tolerated to 8mg qd
Consider reducing diuretic dose prior to start of treatment
CrCl <30mL/min: Not recommended
Initial: 4mg/day given in 1 or 2 divided doses
Monitor BP and titrate carefully w/ doses >8mg
Initial: 2mg qd in the 1st week, followed by 4mg qd in the 2nd week
Maint: 8mg qd if tolerated
Tab: 2mg*, 4mg*, 8mg* *scored
Hereditary or idiopathic angioedema. Coadministration w/ aliskiren in patients w/ diabetes.
Higher incidence of angioedema in blacks than nonblacks. Angioedema of the face, extremities, lips, tongue, glottis, or larynx reported; d/c and administer appropriate therapy. Intestinal angioedema reported; monitor for abdominal pain. Symptomatic hypotension may occur and is most likely in patients w/ volume/salt depletion. Closely monitor patients at risk for excessive hypotension, especially during the first 2 weeks of treatment and whenever dose is increased. May cause agranulocytosis and bone marrow depression, most frequently in renal impairment patients, especially w/ collagen vascular disease (eg, systemic lupus erythematosus [SLE] or scleroderma). May cause changes in renal function. Oliguria, progressive azotemia, and (rarely) acute renal failure and death may occur in patients w/ severe CHF. May increase BUN and SrCr in patients w/ renal artery stenosis. May cause hyperkalemia; risk factors include renal insufficiency and diabetes mellitus (DM). Persistent nonproductive cough reported. Rarely, associated w/ syndrome that starts w/ cholestatic jaundice and progresses to fulminant necrosis and sometimes death; d/c if jaundice or marked elevations of hepatic enzymes develop. Hypotension may occur w/ major surgery or during anesthesia.
Cough, headache, asthenia, dizziness, hypotension.
See Contraindications and Dose modification. Dual blockade of the RAS is associated w/ increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure); avoid combined use of RAS inhibitors, or closely monitor BP, renal function, and electrolytes w/ concomitant agents that affect the RAS. Avoid w/ aliskiren in patients w/ renal impairment (GFR <60mL/min). Hypotension risk, increased BUN and SrCr, and reduced perindoprilat bioavailability w/ diuretics. Increased risk of hyperkalemia w/ K+-sparing diuretics, drugs that increase serum K+ (eg, indomethacin, heparin, cyclosporine), K+ supplements and/or K+-containing salt substitutes. May increase lithium levels and risk of toxicity; monitor lithium levels. Nitritoid reactions reported w/ injectable gold (sodium aurothiomalate). Caution w/ digoxin. Coadministration w/ NSAIDs, including selective COX-2 inhibitors, may attenuate antihypertensive effect of ACE inhibitors and may further deteriorate renal function.
PREGNANCY AND LACTATION
Category D, caution in nursing.
MECHANISM OF ACTION
ACE inhibitor; inhibits ACE activity, resulting in decreased plasma angiotensin II, leading to decreased vasoconstriction, increased plasma renin activity, and decreased aldosterone secretion.
Absorption: Absolute bioavailability (75%, 25% perindoprilat); Tmax=1 hr, 3-7 hrs (perindoprilat). Distribution: Plasma protein binding (approx 60%, 10-20% perindoprilat); crosses placenta. Metabolism: Hepatic (extensive); hydrolysis, glucuronidation, cyclization via dehydration; perindoprilat (active metabolite). Elimination: Urine (4-12%, unchanged); T1/2=approx 0.8-1 hr, 3-10 hrs (perindoprilat).
Assess for hereditary or idiopathic angioedema, volume and/or salt depletion, CHF, renal artery stenosis, ischemic heart disease, cerebrovascular disease, hepatic/renal impairment, DM, collagen vascular disease (eg, SLE), previous hypersensitivity to the drug, pregnancy/nursing status, and possible drug interactions.
Monitor for signs/symptoms of anaphylactoid reactions, head/neck/intestinal angioedema, hypotension, agranulocytosis, bone marrow depression, cholestatic jaundice, fulminant hepatic necrosis, hepatic failure, hyperkalemia, persistent nonproductive cough, hypersensitivity reactions, and neutropenia. Monitor hepatic/renal function, BP, and K+ levels.
Inform of pregnancy risks and discuss treatment options w/ women planning to become pregnant; advise to report pregnancy to physician as soon as possible. Instruct to d/c and immediately report to physician if any signs/symptoms of angioedema develop. Counsel to report any signs of infection (eg, sore throat, fever).
20-25°C (68-77°F). Protect from moisture.
aceondo facebook, aceondo admission list 2014, buy perindopril, aceondo resumption date, aceondo cut off mark, aceon generic, aceondo admission status, buy aceon online, aceon without prescription, buy aceon, purchase perindopril online, aceone technologies, latest aceondo news, order perindopril online, aceondo post utme cut off mark, aceon manufacturer, buy cheap perindopril, aceondo, order perindopril, latest news on aceondo resumption date, aceondo 3rd batch admission list, aceondo strike, generic drug for aceon, aceondo 2nd batch admission list, order aceon, aceondo news, aceon generic equivalent, generic perindopril, aceondo admission list, aceon-bright inc, aceone, aceon, aceonthehouse twitter, aceondo latest news, purchase perindopril, aceondo admission list 2013, buy perindopril online, is aceondo admission list out, aceonthehouse, aceon generic name